Related Experiment Video
Updated: Jun 10, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Is glycogen synthase kinase-3 a central modulator in mood regulation?
1Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. xili@uab.edu
Abstract:
Little is known regarding the mechanisms underlying the complex etiology of mood disorders, represented mainly by major depressive disorder and bipolar disorder. The 1996 discovery that lithium inhibits glycogen synthase kinase-3 (GSK3) raised the possibility that impaired inhibition of GSK3 is associated with mood disorders. This is now supported by evidence from animal biochemical, pharmacological, molecular, and behavioral studies and from human post-mortem brain, peripheral tissue, and genetic studies that are reviewed here. Mood disorders may result in part from impairments in mechanisms controlling the activity of GSK3 or GSK3-regulated functions, and disruptions of these regulating systems at different signaling sites may contribute to the heterogeneity of mood disorders. This substantial evidence supports the conclusion that bolstering the inhibitory control of GSK3 is an important component of the therapeutic actions of drugs used to treat mood disorders and that GSK3 is a valid target for developing new therapeutic interventions.
Insights
Impaired inhibition of glycogen synthase kinase-3 (GSK3) may contribute to mood disorders like depression and bipolar disorder. Targeting GSK3 offers a promising therapeutic strategy for these complex conditions.
Area of Science:
- Neuroscience
- Biochemistry
- Psychiatry
Background:
- The precise mechanisms behind major depressive disorder and bipolar disorder remain largely unknown.
- Lithium's inhibition of glycogen synthase kinase-3 (GSK3) in 1996 suggested a link between GSK3 activity and mood disorders.
Purpose of the Study:
- To review the evidence linking GSK3 to the etiology of mood disorders.
- To explore GSK3 as a potential therapeutic target for mood disorder interventions.
Main Methods:
- Review of animal studies (biochemical, pharmacological, molecular, behavioral).
- Review of human studies (post-mortem brain, peripheral tissue, genetic).
Main Results:
- Substantial evidence supports the association between impaired GSK3 inhibition and mood disorders.
- Disruptions in GSK3 regulation contribute to mood disorder heterogeneity.
Conclusions:
- Enhancing inhibitory control of GSK3 is crucial for the therapeutic effects of mood disorder medications.
- GSK3 is a validated and promising target for novel therapeutic development in mood disorders.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
GPCRs Regulate Adenylyl Cylase Activity
Two...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Regulation of Food Intake
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...